ERNA Earnings — Ernexa Therapeutics Inc. Common Stock Post-ER Performance | BigEarnings
ERNA — Ernexa Therapeutics Inc. Common Stock
XNAS
Price$10.57
Market Cap$12.3M
P/E—
52W Range$3.18 – $88.13
Next Earnings2026-08-12
About Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.